Infographic: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia: the RADIANCE study

The study recruited individuals with visual impairment secondary to myopic CNV with greater than -6D of spherical equivalence and axial length >26 mm. In addition to the exclusions presented in the infographic, the study also excluded patients with a history of stroke, intraocular steroids or surgery 3 months prior to randomization. Both ranibizumab arms received sham PDT at baseline. In group 1, vision stabilisation was defined as no change in BCVA in the previous two monthly visits. In group 2, treatment was discontinued if there was no evidence of disease activity (absence of intraretinal or subretinal fluid on optical coherence tomography imaging, or leakage on fluorescein angiography). Non-inferiority (<5 ETDRS letters) was assessed between groups 1 and 2 to determine the effect of retreatment criteria on vision at 6 months. A mean visual acuity value for the PDT group at 6 months is not presented in the paper. There were no reported cases of endophthalmitis, myocardial infarction or death during the study. CNV – choroidal neovascularisation; BCVA – best corrected visual acuity; ETDRS – early treatment diabetic retinopathy study; PRP – panretinal photocoagulation; VEGF – vascular endothelial growth factor; PDT – photodynamic therapy; PRN –pro re nata (i.e., as needed); AE – adverse events; SAE – serious adverse events.